Availability, prices, and affordability of selected essential cancer medicines in a middle-income country – the case of Mexico
Authors:
Open Access
- 14 May 2020
- journal article
- research article
- Published by Springer Nature in BMC Health Services Research
- Vol. 20 (1) , 1-11
Abstract
Background: More alternatives have become available for the diagnosis and treatment of cancer in low- and middle-income countries. Because of increasing demands, governments are now facing a problem of limited affordability and availability of essential cancer medicines. Yet, precise information about the access to these medicines is limited, and the methodology is not very well developed. We assessed the availability and affordability of essential cancer medicines in Mexico, and compared their prices against those in other countries of the region. Methods: We surveyed 21 public hospitals and 19 private pharmacies in 8 states of Mexico. Data were collected on the availability and prices of 49 essential cancer medicines. Prices were compared against those in Chile, Peru, Brazil, Colombia and PAHO’s Strategic Fund. Results: Of the various medicines, mean availability in public and private sector outlets was 61.2 and 67.5%, respectively. In the public sector, medicines covered by the public health insurance “People’s Health Insurance” were more available. Only seven (public sector) and five (private sector) out of the 49 medicines were considered affordable. Public sector procurement prices were 41% lower than in other countries of the region. Conclusions: The availability of essential cancer medicines, in the public and private sector, falls below World Health Organization’s 80% target. The affordability remains suboptimal as well. A national health insurance scheme could serve as a mechanism to improve access to cancer medicines in the public sector. Comprehensive pricing policies are warranted to improve the affordability of cancer medicines in the private sector.Keywords
All Related Versions
This publication has 36 references indexed in Scilit:
- Access to cancer medications in low- and middle-income countriesNature Reviews Clinical Oncology, 2013
- A new entity for the negotiation of public procurement prices for patented medicines in MexicoBulletin of the World Health Organization, 2012
- The High Cost of Cancer Drugs and What We Can Do About ItMayo Clinic Proceedings, 2012
- Scaling up cancer care for children without medical insurance in developing countries: The case of MexicoPediatric Blood & Cancer, 2012
- Cancer control in developing countries: using health data and health services research to measure and improve access, quality and efficiencyBMC International Health and Human Rights, 2010
- Quantifying the Impoverishing Effects of Purchasing Medicines: A Cross-Country Comparison of the Affordability of Medicines in the Developing WorldPLOS Medicine, 2010
- Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI dataBMC Cardiovascular Disorders, 2010
- Colorectal cancer in Mexico: should a middle income country invest in screening or in treatment?The European Journal of Health Economics, 2009
- Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysisThe Lancet, 2009
- Pharmaceutical Pricing and Reimbursement Policies in SwedenSSRN Electronic Journal, 2007